Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business
Once again, the company exceeded quarterly expectations on the flare-up of another pandemic wave.
However, their core revenue, which was growing 134% last year is going to slow down to grow 28% this year, that’s a huge slowdown which we didn’t see coming.
It’s still a great company with a huge and growing war chest of $935M and terrific management, so longer-term we’re still bullish on the shares.
Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More »